Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Autor: P. Grivas, Y. Loriot, R. Morales-Barrera, M. Y. Teo, Y. Zakharia, S. Feyerabend, N. J. Vogelzang, E. Grande, N. Adra, A. Alva, A. Necchi, A. Rodriguez-Vida, S. Gupta, D. H. Josephs, S. Srinivas, K. Wride, D. Thomas, A. Simmons, A. Loehr, R. L. Dusek, D. Nepert, S. Chowdhury

Publikováno v: BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)

Abstract Background ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in patients with previously treated locally advanced/unresectable or metastatic urothelial carcinoma (UC). Methods Patients with UC were enrolled independent

Externí odkaz: https://doaj.org/article/dbd7ef41f9444e0d96e69e4882bd9a23

Additional file 1 of Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Autor: Grivas, P., Y. Loriot, R. Morales-Barrera, M. Y. Teo, Y. Zakharia, S. Feyerabend, N. J. Vogelzang, E. Grande, N. Adra, A. Alva, A. Necchi, A. Rodriguez-Vida, S. Gupta, D. H. Josephs, S. Srinivas, K. Wride, D. Thomas, A. Simmons, A. Loehr, R. L. Dusek, D. Nepert, S. Chowdhury

Additional file 1: Supplementary Table S1. Most Frequent (≥10% of Patients) Treatment-Related Adverse Events of Any Grade in the Safety Population. Supplementary Table S2. Summary of the Genetic Alterations in Tumor Tissue Samples and Tumor Respons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c063fc717f7e6f07d78e405883bdad06

659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2

Autor: Jeremy Shapiro, Eric Voog, J. Beltman, Joshua Zhang, Anthony A. Golsorkhi, Darrin Despain, N. J. Vogelzang, Brieuc Sautois, M. Green, Simon Paul Watkins, Wassim Abida, Amita Patnaik, Raymond S. McDermott, Richard Martin Bambury, Simon Chowdhury, J. Xiao, Andrew Simmons, David Campbell, Alan H. Bryce

Publikováno v: Annals of Oncology. 31:S533-S534

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2da6639376baa8a98308574915a4ad72
https://doi.org/10.1016/j.annonc.2020.08.918

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Autor: Lawrence Fong, Yves Fradet, Winald R. Gerritsen, David I. Quinn, David J. Vaughn, Daniel P. Petrylak, Joaquim Bellmunt, Howard Gurney, Dean F. Bajorin, R. de Wit, Stéphane Culine, Toni K. Choueiri, J.-L. Lee, Miguel Angel Climent, N. J. Vogelzang, Tara L. Frenkl, Andrea Necchi, Kijoeng Nam, Cora N. Sternberg, Rodolfo F. Perini

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology, vol 30, iss 6
Annals of Oncology
Annals of Oncology, 30(6), 970-976. Elsevier Ltd.
Annals of Oncology, 30, 6, pp. 970-976
Annals of Oncology, 30, 970-976

Background Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4a787c095cc0fd203a7dd10ec701e7
https://escholarship.org/uc/item/0kd723bn

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Autor: Yves Fradet, J.-L. Lee, Andrea Necchi, R. de Wit, David J. Vaughn, Lawrence Fong, Daniel P. Petrylak, David I. Quinn, Stéphane Culine, Erin Jensen, Miguel Angel Climent, Toni K. Choueiri, Winald R. Gerritsen, Joaquim Bellmunt, Howard Gurney, Cora N. Sternberg, Rodolfo F. Perini, Tara L. Frenkl, Dean F. Bajorin, N. J. Vogelzang

Publikováno v: Annals of Oncology. 29:viii320-viii321

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7387460cc0a27a2b2979edab9631f981
https://doi.org/10.1093/annonc/mdy283.110